Clinical Trials Logo

CD22 Positive clinical trials

View clinical trials related to CD22 Positive.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03698552 Recruiting - Clinical trials for Recurrent B Acute Lymphoblastic Leukemia

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Start date: August 24, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of ADCT-602 in treating patients with B-cell lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as ADCT-602, may interfere with the ability of tumor cells to grow and spread.